Cue biopharma announces first patient dosed in part b patient expansion of cue-101 phase 1 monotherapy trial in hpv+ second line and beyond hnscc

Cambridge, mass., june 10, 2021 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted t cells directly within the patient's body, announced today that it has dosed the first patient in the part b expansion phase of its phase 1 monotherapy clinical trial of cue-101 at the recommended phase 2 dose of 4mg/kg.
CUE Ratings Summary
CUE Quant Ranking